Incision & Drainage of Perianal Sepsis in the Immunocompromised: A Need for Heightened Postoperative Awareness
Incision and drainage of perianal sepsis has appreciable success in the immunocompetent population, but outcomes after incision and drainage in the immunosuppressed population are unknown. Immunosuppression is an independent risk factor for major morbidity, return to the operating room, and mortality. With post-operative sepsis the most common complication, inpatient admission and extended duration antibiotic therapy is warranted in immunosuppressed patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 22, 2019 Category: Consumer Health News Source Type: news
Minocycline for Acne Changes Skin Microbiota
(MedPage Today) -- Findings in pilot study may explain adverse effects of antibiotic therapy in acne (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 16, 2019 Category: Dermatology Source Type: news
Patients With Bone Infections May Benefit As Much From Oral Antibiotics As IVs, OVIVA Study Finds
For patients with bone infections, there is no significant difference in response between oral antibiotics and prolonged IV antibiotic therapy per new OVIVA study. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 11, 2019 Category: Pharmaceuticals Authors: Judy Stone, Contributor Source Type: news
IllumiCare inks deal with Minnesota company
IllumiCare has secured a partnership with a Minneapolis-based clinical surveillance company.
The Birmingham-based firm will work with VigiLanz to increase visibility within provider’s and pharmacist’s normal workflows around antimicrobial therapy monitoring.
Financial details were not released to the BBJ.
Illumicare will apply its Smart Ribbon technology with VigiLanz’s Antimicr obial Stewardship Solution. This is intended to increase engagement at hospitals and save pharmacists time tracking… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 7, 2019 Category: Biotechnology Authors: Tyler Patchen Source Type: news
IllumiCare inks deal with Minnesota company
IllumiCare has secured a partnership with a Minneapolis-based clinical surveillance company.
The Birmingham-based firm will work with VigiLanz to increase visibility within provider’s and pharmacist’s normal workflows around antimicrobial therapy monitoring.
Financial details were not released to the BBJ.
Illumicare will apply its Smart Ribbon technology with VigiLanz’s Antimicr obial Stewardship Solution. This is intended to increase engagement at hospitals and save pharmacists time tracking… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 7, 2019 Category: American Health Authors: Tyler Patchen Source Type: news
Cellulitis or Cellulitis Mimic? How to Tell the Difference Cellulitis or Cellulitis Mimic? How to Tell the Difference
Real cases seen by an ID specialist in recent weeks illustrate conditions that can mimic cellulitis and lead to inappropriate antibiotic therapies.Medscape Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2019 Category: Consumer Health News Tags: Infectious Diseases Case Challenge Source Type: news
Management of Neonates Born at 35 0/7 Weeks' Gestation With Suspected or Proven Early-Onset Bacterial Sepsis
The authors of this journal article say that the incidence of neonatal early-onset sepsis (EOS) has declined substantially over the last 2 decades, primarily because of the implementation of evidence-based intrapartum antimicrobial therapy. However, EOS remains a serious and potentially fatal illness. Laboratory tests alone are neither sensitive nor specific enough to guide EOS management decisions. Maternal and infant clinical characteristics can help identify newborn infants who are at risk and guide the administration of empirical antibiotic therapy. The incidence of EOS, the prevalence and implications of estab...
Source: Current Awareness Service for Health (CASH) - January 17, 2019 Category: Consumer Health News Source Type: news
Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
This Cochrane Review was Substantively amended in January 2019. However, there was no change to the conclusion, that Up-to-date evidence of very low to moderate quality, with insufficient sample power per outcome, does not clearly support the use of procalcitonin-guided antimicrobial therapy to minimize mortality, mechanical ventilation, clinical severity, reinfection or duration of antimicrobial therapy of patients with septic conditions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 11, 2019 Category: Consumer Health News Source Type: news
Cellulitis Risk Score May Help Guide IV Antibiotic Therapy in Children Cellulitis Risk Score May Help Guide IV Antibiotic Therapy in Children
Pediatricians from Australia have developed and validated a simple risk-assessment score to help guide decisions regarding antibiotic therapy for cellulitis in children.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 5, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock
This review concludes that there is no adequate, direct evidence as to whether de-escalation of antimicrobial agents is effective and safe for adults with sepsis, severe sepsis or septic shock. The authors say this uncertainty warrants further research via RCTs and the authors are awaiting the results of an ongoing RCT testing the de-escalation of empirical antimicrobial therapy for severe sepsis. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 28, 2018 Category: Consumer Health News Source Type: news
Atlas of Shared Learning: Outpatient parental antibiotic therapy at Whittington Health NHS Trust
This case study outlines how the Lead Outpatient Parenteral Antibiotic Therapy (OPAT) Nurse at Whittington Health NHS Trust led on the development and implementation of new pathways and services, to reduce unwarranted variation by ensuring patients could be discharged home safely and still receive their antibiotic therapy as recommended. This has led to better outcomes, experiences and use of resources. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 5, 2018 Category: Consumer Health News Source Type: news
With these nanoparticles, a simple urine test could diagnose bacterial pneumonia
(Massachusetts Institute of Technology) MIT researchers have now developed a nanoparticle-based technology that could be used distinguish between bacterial and viral forms of pneumonia. The technology could also be used to monitor whether antibiotic therapy has successfully treated the infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 29, 2018 Category: Infectious Diseases Source Type: news
Zimmer Biomet Recalls 1,300 Bone Growth and Spinal Fusion Stimulators
A recall that Zimmer Biomet initiated in February has just been identified by FDA as a Class I recall, marking it the most serious type of medical device recall. The company is recalling 1,360 implantable bone growth and spinal fusion stimulators that are used to help heal bone following spinal fusion surgery or to help heal broken long bones, such as a leg or arm bone. These devices are placed during surgery and are designed to send a low-level electrical signal to encourage the body's natural healing process.
Several sessions at MD&M West 2019 will focus on regulatory and quality issues that i...
Source: MDDI - November 27, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news
Zimmer Biomet recalls bone stimulators on contamination risk
Zimmer Biomet (NYSE:ZBH) recalled nearly 1,400 bone stimulators on the risk that they could be contaminated with bacteria or chemicals, the FDA said yesterday.
The Class I recall, denoting the risk of serious injury or death, covers 1,360 implantable bone growth and spinal fusion stimulators made and distributed between February 2015 and March 2018, including Zimmer Biomet’s Osteogen, SpF Plus-Mini and SpF-XL stimulators, the federal safety watchdog said.
The devices are designed to stimulate healing after spinal fusion procedures or long-bone breaks. The voluntary recall was launched Feb. 19 “due to a lack o...
Source: Mass Device - November 27, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Orthopedics Recalls Regulatory/Compliance Spinal Zimmer Biomet Source Type: news
Diagnostics Are Helping Counter Antimicrobial Resistance, But More Work Is Needed
Antimicrobial resistance (AMR) threats to patient health are becoming more widely recognized and diagnostics manufacturers are making significant progress in combatting the overuse of antibiotics. There is still a lot of work to be done, however. A recent health scare for Rick Bright, Ph.D., director of the Biomedical Advanced Research and Development Authority (BARDA), HHS, the very agency working to combat emerging infectious diseases (EID) and other threats, highlights the lingering risks.Â
During the 10th Public Meeting of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB...
Source: MDDI - November 20, 2018 Category: Medical Devices Authors: Daphne Allen Tags: IVD Source Type: news
